Robustness of Plasma P-Tau217 Diagnostic Thresholds for Alzheimer Disease Across Various Clinical Populations and Laboratory Environments
BACKGROUND AND OBJECTIVES: Blood-based biomarkers (BBMs), especially plasma tau phosphorylated at threonine 217 (p-tau217), could scale Alzheimer disease (AD) clinical-biological diagnosis, but clinical use requires thresholds transferable across laboratories and populations. We compared Lumipulse p-tau217 with other BBMs; evaluated amyloid-anchored thresholds across centers, analyzers, reagent lots, and clinical populations; and assessed second-line CSF adjudication of gray zone results. METHODS: This multicenter, cross-sectional diagnostic-classification study included an exploratory Brussels cohort and 3 external validation cohorts. Brussels participants were cognitively unimpaired or impaired and had Aβ status determined by amyloid-PET or CSF Aβ42 and tau status by tau-PET or CSF p-tau181. Validation cohorts comprised consecutive Paris memory-clinic patients, patients with early-onset neurodegenerative dementia in Bordeaux, and individuals with monogenic frontotemporal lobar degeneration (FTLD). Plasma p-tau217 was measured locally on Lumipulse analyzers. BBMs and ratios were compared using receiver operating characteristic (ROC) analyses. In Brussels, a Youden cutoff and dual 95% or 97.5% sensitivity/specificity cutoffs were derived; intermediate values defined gray zones. RESULTS: < 0.0001). The 0.193 pg/mL Youden cutoff (95% CI 0.178-0.213) yielded 91.5% sensitivity (95% CI 84.7-95.5) and 91.6% specificity (95% CI 84.8-95.5) and detected neocortical tau-PET positivity with 98.5% sensitivity and 81.8% specificity. In Paris, sensitivity/specificity for clinical-biological AD were 93.2% (95% CI 85.1-97.1)/93.0% (95% CI 81.4-97.6); in Bordeaux, sensitivity/specificity for clinical-biological AD were 95.7% (95% CI 79.0-99.2)/92.3% (95% CI 66.7-98.6). Specificity in monogenic FTLD was 88.4% (95% CI 75.5-94.9). False-positive classifications were enriched in FTLD with amyotrophic lateral sclerosis (ALS). Dual thresholds yielded gray zones in 15.4%-24.8% of Paris patients; second-line CSF testing resolved 86.2%-88.9% of gray zone cases. DISCUSSION: Lumipulse plasma p-tau217 thresholds were transferable across centers, analyzers, reagent lots, and heterogeneous clinical populations, supporting evaluation of plasma-first pathways with confirmatory testing for gray zone values. Values below 0.193 pg/mL made neocortical tauopathy unlikely. Limitations include cross-sectional design, specialized Western European recruitment, unavailable race/ethnicity data, heterogeneous reference standards, incomplete AD copathology adjudication in monogenic FTLD, and no cross-platform comparison.
Authors
- Lara Huyghe (ORCID: https://orcid.org/0009-0009-3568-3474)
- Jean‐Louis Bayart (ORCID: https://orcid.org/0000-0003-2043-3455)
- Pascal Kienlen‐Campard (ORCID: https://orcid.org/0000-0003-1086-2942)
- Aurélie Bedel (ORCID: https://orcid.org/0000-0003-1226-1753)
- Renaud Lhommel (ORCID: https://orcid.org/0000-0003-0668-6122)
- Adrian Ivanoiu
- Nicolas Villain (ORCID: https://orcid.org/0000-0002-7429-4289)
- Thomas Gérard (ORCID: https://orcid.org/0000-0001-7997-3945)
- Hassan Elmazria
- Gaëtane Picard
- Isabelle Le Ber (ORCID: https://orcid.org/0000-0002-2508-5181)
- Bernard Jimmy Hanseeuw (ORCID: https://orcid.org/0000-0002-3102-6778)
- Lisa Quenon (ORCID: https://orcid.org/0000-0001-9139-2422)
- Yasmine Salman (ORCID: https://orcid.org/0000-0002-8564-5136)
- Lise Colmant (ORCID: https://orcid.org/0009-0006-6511-0819)
- Stéphanie Bombois (ORCID: https://orcid.org/0000-0003-3117-1833)
- Giulia Dingeo (ORCID: https://orcid.org/0000-0001-8787-8526)
- Jonathan Douxfils (ORCID: https://orcid.org/0000-0002-7644-5298)
- Sarra Bahroun (ORCID: https://orcid.org/0009-0008-3419-7231)
- Vincent Planche (ORCID: https://orcid.org/0000-0003-3713-227X)
- Emilien Boyer (ORCID: https://orcid.org/0009-0009-6222-4580)
- Clara David (ORCID: https://orcid.org/0000-0002-1410-6629)
- Foudil Lamari (ORCID: https://orcid.org/0000-0002-5104-2935)
- Richard Lévy
- Fabienne Clot
- Sophie Auriacombe (ORCID: https://orcid.org/0000-0002-6122-9808)
- Fatimah Nabeebaccus (ORCID: https://orcid.org/0009-0005-8435-9030)
- Emmanuelle Durand
Institutions
- Centre National de la Recherche Scientifique (FR)
- Cliniques Universitaires Saint-Luc (BE)
- Harvard University (US)
- University of Namur (BE)
- Université de Bordeaux (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Sorbonne Université (FR)
- Institut des Maladies Neurodégénératives (FR)
- Clinique Saint Pierre (BE)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut du Cerveau (FR)
- Namur Research Institute for Life Sciences (BE)
- BoRdeaux Institute of onCology (FR)
- UCLouvain (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Neurology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1212/wnl.0000000000218784
- Citations
- 4
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 10.88
Funders
- Siemens Healthineers
- Servier
- FONDATION ALZHEIMER